Press release - 27/08/2018 Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-tar
Article - 25/04/2018 Resistance, immunity and malaria vaccination People who have survived a malaria infection often develop immunity to the disease. International malaria research is aimed at exploiting a person's natural immunity in order to treat malaria effectively and avoid resistance to previously effective drugs. These new approaches also raise hopes that one day countries at high risk of malaria may be able to eradicate the devastating disease. https://www.gesundheitsindustrie-bw.de/en/article/news/resistance-immunity-and-malaria-vaccination
Transregional research cooperation - 11/10/2017 New research consortium to develop new liver cancer treatments The causes, signs and symptoms of liver cancer are extremely complex. Investigating them requires the collaboration of many experts across university and regional boundaries. A new transregional research group is now studying the complex overall mechanisms at the cellular, genetic and molecular level in order to develop new concepts and drugs for treating liver and bile duct cancers.https://www.gesundheitsindustrie-bw.de/en/article/news/new-research-consortium-to-develop-new-liver-cancer-treatments
Press release - 04/10/2017 Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
Press release - 05/09/2017 Cell marking opens up a window into the body A new and particularly reliable method for marking cells can simplify research into diseases such as myocardial infarction, diabetes or Alzheimer's and reduce the use of test animals: Scientists from the University of Tübingen have developed a method by which they can target specific cell types in mice and monitor their behavior using positron emission tomography (PET). PET-based cell tracking allows scientists to observe complex life…https://www.gesundheitsindustrie-bw.de/en/article/press-release/cell-marking-opens-up-a-window-into-the-body
Article - 22/08/2017 Transgenic mice in influenza research – risk assessment and vaccine development A research team from Freiburg is developing a method for identifying human influenza viruses of animal origin. This could potentially improve measures taken to prevent imminent pandemics. The researchers are working with genetically modified mice. Transgenic mice also play a role in the development of a ’universal’ influenza vaccine. https://www.gesundheitsindustrie-bw.de/en/article/news/transgenic-mice-in-influenza-research-risk-assessment-and-vaccine-development
Article - 04/07/2017 Ruxolitinib – successful graft-versus-host disease treatment Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect.…https://www.gesundheitsindustrie-bw.de/en/article/news/ruxolitinib-successful-graft-versus-host-disease-treatment
Article - 26/06/2017 Hope for mRNA vaccines despite damper The pressure is on to develop novel vaccines based on messenger RNA and aimed at combating cancer and protecting against pandemics. Although mRNA vaccination as a cancer monotherapy has suffered a setback this year, the industry is nevertheless confident that it will succeed because of existing proof that mRNA vaccines stimulate the body's immune defence.https://www.gesundheitsindustrie-bw.de/en/article/news/hope-for-mrna-vaccines-despite-damper
Press release - 23/05/2017 TolerogenixX secures seed funding and completes Phase I clinical trial TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance this innovative technique and the preparations for Phase II of the clinical trial, which begins in spring 2018. Further…https://www.gesundheitsindustrie-bw.de/en/article/press-release/tolerogenixx-secures-seed-funding-and-completes-phase-i-clinical-trial
Article - 18/05/2017 ImmuStick – novel rapid test for identifying disease pathogens In some situations such as in the food and pharmaceutical industries or hospitals, a test to identify disease pathogens can be vital. At present, such tests are relatively time-consuming and can take hours or even days to produce results, depending on the pathogen. Scientists from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are currently developing a rapid test called ImmuStick which is as easy to use…https://www.gesundheitsindustrie-bw.de/en/article/news/immustick-novel-rapid-test-for-identifying-disease-pathogens
24 - 30 April 2017 European Immunization Week From 24 till 30 April 2017 is "European Immunization Week" – the BIOPRO provides information about this topic. Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target…https://www.gesundheitsindustrie-bw.de/en/article/news/european-immunization-week
Article - 20/09/2016 CRISPR-Cas has more surprises in store Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
Article - 05/09/2016 Apogenix: immuno-oncological protein drugs for the treatment of malignant diseases Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-immunonkologische-proteinwirkstoffe-gegen-maligne-erkrankungen
Article - 22/08/2016 Ad-O-Lytics – a new biotech start-up from Ulm A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
Article - 18/08/2016 Chronic viral infections of the liver Hepatitis B and hepatitis C are two of the most common infectious diseases in the world. They often take a chronic course and carry a high risk of progressing to cirrhosis and hepatocellular carcinoma. A new transregional collaborative research centre involving scientists from Heidelberg and Freiburg is looking into how hepatitis B and hepatitis C viruses, which have different symptoms and treatments, are able to evade the immune system and allow…https://www.gesundheitsindustrie-bw.de/en/article/news/chronic-viral-infections-of-the-liver
Article - 21/07/2016 New anticancer drugs – hop compounds have the potential to treat cancer Secondary hop compounds appear to have a positive effect on the immune system and therefore have the potential to be used for the treatment and prevention of cancer. However, the bioavailability of hop compounds in the human body is relatively poor. Researchers from Hohenheim and Tübingen are therefore looking for a way to increase their absorption rate.https://www.gesundheitsindustrie-bw.de/en/article/news/new-drugs-for-the-treatment-of-cancer-hop-compounds-have-the-potential-to-treat-cancer
Article - 19/07/2016 Licence to kill – the enormous potential of CAR T cells With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
Press release - 14/07/2016 Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines CureVac AG, the most clinically advanced mRNA company, today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine. The study demonstrated a mechanistic insight into the mode of action and rationale for the use of messenger RNA (mRNA) for the development of multiple vaccines.https://www.gesundheitsindustrie-bw.de/en/article/press-release/study-in-peer-reviewed-journal-vaccine-demonstrates-decoding-mode-of-action-of-mrna-vaccines
Article - 11/07/2016 The toxin of natural killer cells Natural killer cells kill tumour cells by injecting the protein HMGB1, which blocks the production of cellular energy by aerobic respiration. Researchers from Heidelberg have elucidated this previously unknown cancer defence mechanism and are now in the process of developing a new immunotherapy for treating cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/news/the-toxin-of-natural-killer-cells
Article - 23/06/2016 The body’s immune system loosens artificial joints Hip and knee endoprostheses are not nearly as long-lasting as their natural counterparts. Dr. Ulrike Dapunt from the University Hospital Heidelberg’s Department of Orthopaedics and Traumatology has now discovered that it is not the bacterial activity or secretions that lead to the degradation of bone during chronic inflammation, but rather local host defence mechanisms.https://www.gesundheitsindustrie-bw.de/en/article/news/the-bodys-immune-system-loosens-artificial-joints
Article - 20/06/2016 Activation of the innate immune system against metastatic colorectal cancer Researchers from Heidelberg have shown that instead of fighting cancer cells, macrophages of the innate immune system promote the growth of metastases in people with metastatic colorectal cancer. They have also shown that a signal inhibitor used to treat HIV infections reactivates macrophages so that they gain the ability to destroy cancer cells. A clinical phase I study has confirmed the antitumoral effects of this drug.https://www.gesundheitsindustrie-bw.de/en/article/news/activation-of-the-innate-immune-system-against-metastatic-colorectal-cancer
Article - 02/05/2016 Hepatitis C: a new starting point for vaccine development With approximately 150,000 infected people in Germany, hepatitis C is a common disease for which therapies, but no vaccine, are available. Dr. Tobias Böttler from the Freiburg University Medical Center and his team are exploring the body’s immune response to the hepatitis C virus (HCV) and have found valuable information that could be used for vaccine development.https://www.gesundheitsindustrie-bw.de/en/article/news/hepatitis-c-a-new-starting-point-for-vaccine-development
Article - 22/02/2016 Generating malaria parasite gene deletion mutants The fight against malaria is one of the targets of goal 3 of the Sustainable Development Goals (SDGs) (ensuring healthy lives and promote well-being for all at all ages). The research carried out by Prof. Dr. Frischknecht and Mirko Singer from the Centre for Infectious Diseases at Heidelberg University Hospital is one of several steps towards eradicating malaria. https://www.gesundheitsindustrie-bw.de/en/article/news/generating-malaria-parasite-gene-deletion-mutants
Article - 15/02/2016 Bacteria – a treasure box for genetic engineers Bacteria have developed a versatile defence system to protect themselves against viral infections. One of these defence tools, known as CRISPR/Cas9 system, is currently hogging the headlines as it promises to revolutionise the way genetic material can be modified. Prof. Rolf Backofen from the Institute of Bioinformatics at the University of Freiburg has managed to classify the defence system of all bacterial species sequenced to date. This will…https://www.gesundheitsindustrie-bw.de/en/article/news/bacteria-a-treasure-box-for-genetic-engineers
Article - 08/02/2016 MalVa GmbH – a protein cocktail that could potentially produce a high protection malaria vaccine MalVa GmbH was founded as a spin-off company of Heidelberg University Hospital around five years ago and its aim is to develop an effective and safe inactivated vaccine against malaria. MalVa GmbH’s innovative strategy to combat this infectious disease involves a cocktail of several parasite antigens. https://www.gesundheitsindustrie-bw.de/en/article/news/malva-gmbh-a-protein-cocktail-that-could-potentially-produce-a-high-protection-malaria-vaccine